Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:AGEN

Agenus Q4 2025 Earnings Results & Report

Agenus logo
$6.50 -0.45 (-6.47%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$6.58 +0.08 (+1.23%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agenus beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 16, 2026. The company reported EPS of $0.56 versus the -$1.27 consensus estimate, while revenue of $34.20 million topped the $28.10 million estimate by $6.11 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Agenus EPS Results

Actual EPS
$0.56
Consensus EPS
-$1.27
Beat/Miss
Beat by +$1.83
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Agenus Revenue Results

Actual Revenue
$34.20 million
Expected Revenue
$28.10 million
Beat/Miss
Beat by +$6.11 million
YoY Revenue Growth
N/A

Upcoming Earnings

Agenus' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Agenus' Q4 2025 Press ReleasePress Release
(8-K)
Agenus' Q4 2025 Annual reportAnnual report
(10-K)

Agenus Q4 2025 Earnings FAQ

Agenus (NASDAQ:AGEN) reported earnings of $0.56 per share for Q4 2025, beating the consensus estimate of -$1.27. The report was announced on Monday, March 16, 2026.

Agenus reported revenue of $34.20 million for Q4 2025, against a consensus estimate of $28.10 million.

Agenus' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Agenus on the company's earnings history page.

Agenus Earnings Headlines

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/agenus-participate-chardan-10th-annual-192300804.html
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
October 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261009464799/en/agenus-to-participate-in-chardan%e2%80%99s-10th-annual-healthcare-investor-conference/
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
 |  Stansberry Research (Ad)
Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/agenus-gets-armenia-approval-botensilimab-120145302.html
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
October 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261008022628/en/Armenia-Grants-First-Marketing-Authorizations-for-Agenus%E2%80%99-BOTBAL-in-Previously-Treated-MSS-Metastatic-Colorectal-Cancer/
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
October 8, 2026  |  financialpost.comF
See More Agenus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Agenus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Agenus and other key companies, straight to your email.

About Agenus

Agenus (NASDAQ:AGEN) (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers. Agenus also develops additional immune checkpoint inhibitors, bispecific antibodies and cancer vaccine technologies intended to address different aspects of the tumor microenvironment.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011. Headquartered in Lexington, Massachusetts, Agenus conducts research and clinical development activities through operations and collaborations supporting programs in the United States and internationally. Garo H. Armen, Ph.D., is the company’s co-founder and chief executive officer.

View Agenus Profile
Earnings Tools